Loading…
NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus
Summary 1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients. 2. In all, 170 patient...
Saved in:
| Published in: | Clinical and experimental pharmacology & physiology 2011-08, Vol.38 (8), p.550-554 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3578-a5f026bb1360d20dc0b73c84e88f0fb15b0eb01493ef2d89ffb1b61261f0b1993 |
|---|---|
| cites | |
| container_end_page | 554 |
| container_issue | 8 |
| container_start_page | 550 |
| container_title | Clinical and experimental pharmacology & physiology |
| container_volume | 38 |
| creator | Sheng, Fei-Feng Dai, Xing-Ping Qu, Jian Lei, Guang-Hua Lu, Hong-Bin Wu, Jing Xu, Xiao-Jing Pei, Qi Dong, Min Liu, Ying-Zi Zhou, Hong-Hao Liu, Zhao-Qian |
| description | Summary
1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients.
2. In all, 170 patients with T2DM and 129 healthy controls were genotyped for NAMPT‐948G>T and ‐3186C>T polymorphisms. Thirty‐five patients with different NAMPT ‐3186 C/T genotypes and the same organic anion‐transporting polypeptide 1B1 (OATP1B1521) T/C genotype were randomly selected to undergo 8 weeks preprandial repaglinide treatment (1 mg, three times daily). Serum fasting plasma glucose (FPG), post‐prandial plasma glucose (PPG), glycated haemoglobin (HbAlc), fasting serum insulin (FINS), post‐prandial serum insulin (PINS), triglyceride (TG), total cholesterol (CHO), homeostasis model assessment of insulin resistance (HOMA‐IR), low‐density lipoprotein–cholesterol (LDL‐C) and high‐density lipoprotein–cholesterol (HDL‐C) were determined before and after repaglinide treatment.
3. After repaglinide treatment for 8 consecutive weeks, there were significantly decreases in PFG, PPG, HbAlc, CHO and LDL‐C, and increases in FINS, HDL‐C and the HDL‐C : LDL‐C ratio, in T2DM patients. The elevated PINS value in patients with CT genotypes was significantly lower than that in patients with the CC and TT genotypes (P |
| doi_str_mv | 10.1111/j.1440-1681.2011.05548.x |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_879677174</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>879677174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3578-a5f026bb1360d20dc0b73c84e88f0fb15b0eb01493ef2d89ffb1b61261f0b1993</originalsourceid><addsrcrecordid>eNo9kUuP0zAUhS0EYsrAX0DesUrm3jh-ZMFiFE0HpGGooIilFSc31CUv4lTT_nsSOtQbH_l-58o6hzGOEON8bvYxpilEqAzGCSDGIGVq4uMLtroMXrIVCJARGg1X7E0IewCQoMRrdpWgEig1rNj-8fbLZssjgUblN1s-9M2p7cdh50PLi7qmcgp8pKH41fjOVzTrMPRdIO47nu98R7McislTN4NPftrx7WkgnvDKF44mCrylpvHTIbxlr-qiCfTu-b5mP9Z32_xT9PD1_nN--xCVQmoTFbKGRDmHQkGVQFWC06I0KRlTQ-1QOiAHmGaC6qQyWT2_OYWJwhocZpm4Zh_Oe4ex_3OgMNnWh3L-RNFRfwjW6ExpjTqdyffP5MG1VNlh9G0xnuz_eGbg4xl48g2dLnMEu9Rg93ZJ2y5p26UG-68Ge7T53WZRsz86-32Y6HjxF-Nvq7TQ0v58vLfr75vcfBNrK8VfDp6Jdg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879677174</pqid></control><display><type>article</type><title>NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus</title><source>EBSCOhost SPORTDiscus with Full Text</source><source>Wiley</source><creator>Sheng, Fei-Feng ; Dai, Xing-Ping ; Qu, Jian ; Lei, Guang-Hua ; Lu, Hong-Bin ; Wu, Jing ; Xu, Xiao-Jing ; Pei, Qi ; Dong, Min ; Liu, Ying-Zi ; Zhou, Hong-Hao ; Liu, Zhao-Qian</creator><creatorcontrib>Sheng, Fei-Feng ; Dai, Xing-Ping ; Qu, Jian ; Lei, Guang-Hua ; Lu, Hong-Bin ; Wu, Jing ; Xu, Xiao-Jing ; Pei, Qi ; Dong, Min ; Liu, Ying-Zi ; Zhou, Hong-Hao ; Liu, Zhao-Qian</creatorcontrib><description>Summary
1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients.
2. In all, 170 patients with T2DM and 129 healthy controls were genotyped for NAMPT‐948G>T and ‐3186C>T polymorphisms. Thirty‐five patients with different NAMPT ‐3186 C/T genotypes and the same organic anion‐transporting polypeptide 1B1 (OATP1B1521) T/C genotype were randomly selected to undergo 8 weeks preprandial repaglinide treatment (1 mg, three times daily). Serum fasting plasma glucose (FPG), post‐prandial plasma glucose (PPG), glycated haemoglobin (HbAlc), fasting serum insulin (FINS), post‐prandial serum insulin (PINS), triglyceride (TG), total cholesterol (CHO), homeostasis model assessment of insulin resistance (HOMA‐IR), low‐density lipoprotein–cholesterol (LDL‐C) and high‐density lipoprotein–cholesterol (HDL‐C) were determined before and after repaglinide treatment.
3. After repaglinide treatment for 8 consecutive weeks, there were significantly decreases in PFG, PPG, HbAlc, CHO and LDL‐C, and increases in FINS, HDL‐C and the HDL‐C : LDL‐C ratio, in T2DM patients. The elevated PINS value in patients with CT genotypes was significantly lower than that in patients with the CC and TT genotypes (P < 0.05) and there were significant differences in CHO between patients with the CT genotype and the CC or TT genotype (P < 0.05).
4. The data suggest that the NAMPT ‐3186C>T polymorphism is significantly associated with plasma levels of PINS and CHO in Chinese T2DM patients with repaglinide monotherapy.</description><identifier>ISSN: 0305-1870</identifier><identifier>EISSN: 1440-1681</identifier><identifier>DOI: 10.1111/j.1440-1681.2011.05548.x</identifier><identifier>PMID: 21631570</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adult ; Aged ; Alleles ; Asian Continental Ancestry Group - genetics ; Carbamates - pharmacology ; Carbamates - therapeutic use ; Cholesterol - blood ; Cholesterol - metabolism ; Control Groups ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - genetics ; efficacy ; Female ; Genetic Predisposition to Disease - ethnology ; Genotype ; Humans ; Hypoglycemic Agents - pharmacology ; Hypoglycemic Agents - therapeutic use ; Insulin - blood ; Insulin - metabolism ; Male ; Middle Aged ; nicotinamide phosphoribosyltransferase ; Nicotinamide Phosphoribosyltransferase - genetics ; Piperidines - pharmacology ; Piperidines - therapeutic use ; polymorphism ; Polymorphism, Genetic ; Polymorphism, Single Nucleotide ; repaglinide ; Treatment Outcome ; Type 2 diabetes</subject><ispartof>Clinical and experimental pharmacology & physiology, 2011-08, Vol.38 (8), p.550-554</ispartof><rights>2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd</rights><rights>2011 The Authors. Clinical and Experimental Pharmacology and Physiology © 2011 Blackwell Publishing Asia Pty Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3578-a5f026bb1360d20dc0b73c84e88f0fb15b0eb01493ef2d89ffb1b61261f0b1993</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21631570$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sheng, Fei-Feng</creatorcontrib><creatorcontrib>Dai, Xing-Ping</creatorcontrib><creatorcontrib>Qu, Jian</creatorcontrib><creatorcontrib>Lei, Guang-Hua</creatorcontrib><creatorcontrib>Lu, Hong-Bin</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Xu, Xiao-Jing</creatorcontrib><creatorcontrib>Pei, Qi</creatorcontrib><creatorcontrib>Dong, Min</creatorcontrib><creatorcontrib>Liu, Ying-Zi</creatorcontrib><creatorcontrib>Zhou, Hong-Hao</creatorcontrib><creatorcontrib>Liu, Zhao-Qian</creatorcontrib><title>NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus</title><title>Clinical and experimental pharmacology & physiology</title><addtitle>Clin Exp Pharmacol Physiol</addtitle><description>Summary
1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients.
2. In all, 170 patients with T2DM and 129 healthy controls were genotyped for NAMPT‐948G>T and ‐3186C>T polymorphisms. Thirty‐five patients with different NAMPT ‐3186 C/T genotypes and the same organic anion‐transporting polypeptide 1B1 (OATP1B1521) T/C genotype were randomly selected to undergo 8 weeks preprandial repaglinide treatment (1 mg, three times daily). Serum fasting plasma glucose (FPG), post‐prandial plasma glucose (PPG), glycated haemoglobin (HbAlc), fasting serum insulin (FINS), post‐prandial serum insulin (PINS), triglyceride (TG), total cholesterol (CHO), homeostasis model assessment of insulin resistance (HOMA‐IR), low‐density lipoprotein–cholesterol (LDL‐C) and high‐density lipoprotein–cholesterol (HDL‐C) were determined before and after repaglinide treatment.
3. After repaglinide treatment for 8 consecutive weeks, there were significantly decreases in PFG, PPG, HbAlc, CHO and LDL‐C, and increases in FINS, HDL‐C and the HDL‐C : LDL‐C ratio, in T2DM patients. The elevated PINS value in patients with CT genotypes was significantly lower than that in patients with the CC and TT genotypes (P < 0.05) and there were significant differences in CHO between patients with the CT genotype and the CC or TT genotype (P < 0.05).
4. The data suggest that the NAMPT ‐3186C>T polymorphism is significantly associated with plasma levels of PINS and CHO in Chinese T2DM patients with repaglinide monotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Alleles</subject><subject>Asian Continental Ancestry Group - genetics</subject><subject>Carbamates - pharmacology</subject><subject>Carbamates - therapeutic use</subject><subject>Cholesterol - blood</subject><subject>Cholesterol - metabolism</subject><subject>Control Groups</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - genetics</subject><subject>efficacy</subject><subject>Female</subject><subject>Genetic Predisposition to Disease - ethnology</subject><subject>Genotype</subject><subject>Humans</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - blood</subject><subject>Insulin - metabolism</subject><subject>Male</subject><subject>Middle Aged</subject><subject>nicotinamide phosphoribosyltransferase</subject><subject>Nicotinamide Phosphoribosyltransferase - genetics</subject><subject>Piperidines - pharmacology</subject><subject>Piperidines - therapeutic use</subject><subject>polymorphism</subject><subject>Polymorphism, Genetic</subject><subject>Polymorphism, Single Nucleotide</subject><subject>repaglinide</subject><subject>Treatment Outcome</subject><subject>Type 2 diabetes</subject><issn>0305-1870</issn><issn>1440-1681</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNo9kUuP0zAUhS0EYsrAX0DesUrm3jh-ZMFiFE0HpGGooIilFSc31CUv4lTT_nsSOtQbH_l-58o6hzGOEON8bvYxpilEqAzGCSDGIGVq4uMLtroMXrIVCJARGg1X7E0IewCQoMRrdpWgEig1rNj-8fbLZssjgUblN1s-9M2p7cdh50PLi7qmcgp8pKH41fjOVzTrMPRdIO47nu98R7McislTN4NPftrx7WkgnvDKF44mCrylpvHTIbxlr-qiCfTu-b5mP9Z32_xT9PD1_nN--xCVQmoTFbKGRDmHQkGVQFWC06I0KRlTQ-1QOiAHmGaC6qQyWT2_OYWJwhocZpm4Zh_Oe4ex_3OgMNnWh3L-RNFRfwjW6ExpjTqdyffP5MG1VNlh9G0xnuz_eGbg4xl48g2dLnMEu9Rg93ZJ2y5p26UG-68Ge7T53WZRsz86-32Y6HjxF-Nvq7TQ0v58vLfr75vcfBNrK8VfDp6Jdg</recordid><startdate>201108</startdate><enddate>201108</enddate><creator>Sheng, Fei-Feng</creator><creator>Dai, Xing-Ping</creator><creator>Qu, Jian</creator><creator>Lei, Guang-Hua</creator><creator>Lu, Hong-Bin</creator><creator>Wu, Jing</creator><creator>Xu, Xiao-Jing</creator><creator>Pei, Qi</creator><creator>Dong, Min</creator><creator>Liu, Ying-Zi</creator><creator>Zhou, Hong-Hao</creator><creator>Liu, Zhao-Qian</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201108</creationdate><title>NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus</title><author>Sheng, Fei-Feng ; Dai, Xing-Ping ; Qu, Jian ; Lei, Guang-Hua ; Lu, Hong-Bin ; Wu, Jing ; Xu, Xiao-Jing ; Pei, Qi ; Dong, Min ; Liu, Ying-Zi ; Zhou, Hong-Hao ; Liu, Zhao-Qian</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3578-a5f026bb1360d20dc0b73c84e88f0fb15b0eb01493ef2d89ffb1b61261f0b1993</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alleles</topic><topic>Asian Continental Ancestry Group - genetics</topic><topic>Carbamates - pharmacology</topic><topic>Carbamates - therapeutic use</topic><topic>Cholesterol - blood</topic><topic>Cholesterol - metabolism</topic><topic>Control Groups</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - genetics</topic><topic>efficacy</topic><topic>Female</topic><topic>Genetic Predisposition to Disease - ethnology</topic><topic>Genotype</topic><topic>Humans</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - blood</topic><topic>Insulin - metabolism</topic><topic>Male</topic><topic>Middle Aged</topic><topic>nicotinamide phosphoribosyltransferase</topic><topic>Nicotinamide Phosphoribosyltransferase - genetics</topic><topic>Piperidines - pharmacology</topic><topic>Piperidines - therapeutic use</topic><topic>polymorphism</topic><topic>Polymorphism, Genetic</topic><topic>Polymorphism, Single Nucleotide</topic><topic>repaglinide</topic><topic>Treatment Outcome</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sheng, Fei-Feng</creatorcontrib><creatorcontrib>Dai, Xing-Ping</creatorcontrib><creatorcontrib>Qu, Jian</creatorcontrib><creatorcontrib>Lei, Guang-Hua</creatorcontrib><creatorcontrib>Lu, Hong-Bin</creatorcontrib><creatorcontrib>Wu, Jing</creatorcontrib><creatorcontrib>Xu, Xiao-Jing</creatorcontrib><creatorcontrib>Pei, Qi</creatorcontrib><creatorcontrib>Dong, Min</creatorcontrib><creatorcontrib>Liu, Ying-Zi</creatorcontrib><creatorcontrib>Zhou, Hong-Hao</creatorcontrib><creatorcontrib>Liu, Zhao-Qian</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and experimental pharmacology & physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sheng, Fei-Feng</au><au>Dai, Xing-Ping</au><au>Qu, Jian</au><au>Lei, Guang-Hua</au><au>Lu, Hong-Bin</au><au>Wu, Jing</au><au>Xu, Xiao-Jing</au><au>Pei, Qi</au><au>Dong, Min</au><au>Liu, Ying-Zi</au><au>Zhou, Hong-Hao</au><au>Liu, Zhao-Qian</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus</atitle><jtitle>Clinical and experimental pharmacology & physiology</jtitle><addtitle>Clin Exp Pharmacol Physiol</addtitle><date>2011-08</date><risdate>2011</risdate><volume>38</volume><issue>8</issue><spage>550</spage><epage>554</epage><pages>550-554</pages><issn>0305-1870</issn><eissn>1440-1681</eissn><abstract>Summary
1. In the present study, we investigated the associations of nicotinamide phosphoribosyltransferase (NAMPT)‐3186 C/T and ‐948G/T polymorphisms with the risk of Type 2 diabetes mellitus (T2DM) and their impact on the efficacy of repaglinide in Chinese Han T2DM patients.
2. In all, 170 patients with T2DM and 129 healthy controls were genotyped for NAMPT‐948G>T and ‐3186C>T polymorphisms. Thirty‐five patients with different NAMPT ‐3186 C/T genotypes and the same organic anion‐transporting polypeptide 1B1 (OATP1B1521) T/C genotype were randomly selected to undergo 8 weeks preprandial repaglinide treatment (1 mg, three times daily). Serum fasting plasma glucose (FPG), post‐prandial plasma glucose (PPG), glycated haemoglobin (HbAlc), fasting serum insulin (FINS), post‐prandial serum insulin (PINS), triglyceride (TG), total cholesterol (CHO), homeostasis model assessment of insulin resistance (HOMA‐IR), low‐density lipoprotein–cholesterol (LDL‐C) and high‐density lipoprotein–cholesterol (HDL‐C) were determined before and after repaglinide treatment.
3. After repaglinide treatment for 8 consecutive weeks, there were significantly decreases in PFG, PPG, HbAlc, CHO and LDL‐C, and increases in FINS, HDL‐C and the HDL‐C : LDL‐C ratio, in T2DM patients. The elevated PINS value in patients with CT genotypes was significantly lower than that in patients with the CC and TT genotypes (P < 0.05) and there were significant differences in CHO between patients with the CT genotype and the CC or TT genotype (P < 0.05).
4. The data suggest that the NAMPT ‐3186C>T polymorphism is significantly associated with plasma levels of PINS and CHO in Chinese T2DM patients with repaglinide monotherapy.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>21631570</pmid><doi>10.1111/j.1440-1681.2011.05548.x</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-1870 |
| ispartof | Clinical and experimental pharmacology & physiology, 2011-08, Vol.38 (8), p.550-554 |
| issn | 0305-1870 1440-1681 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_879677174 |
| source | EBSCOhost SPORTDiscus with Full Text; Wiley |
| subjects | Adult Aged Alleles Asian Continental Ancestry Group - genetics Carbamates - pharmacology Carbamates - therapeutic use Cholesterol - blood Cholesterol - metabolism Control Groups Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - genetics efficacy Female Genetic Predisposition to Disease - ethnology Genotype Humans Hypoglycemic Agents - pharmacology Hypoglycemic Agents - therapeutic use Insulin - blood Insulin - metabolism Male Middle Aged nicotinamide phosphoribosyltransferase Nicotinamide Phosphoribosyltransferase - genetics Piperidines - pharmacology Piperidines - therapeutic use polymorphism Polymorphism, Genetic Polymorphism, Single Nucleotide repaglinide Treatment Outcome Type 2 diabetes |
| title | NAMPT -3186C/T polymorphism affects repaglinide response in Chinese patients with Type 2 diabetes mellitus |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T21%3A21%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NAMPT%20-3186C/T%20polymorphism%20affects%20repaglinide%20response%20in%20Chinese%20patients%20with%20Type%202%20diabetes%20mellitus&rft.jtitle=Clinical%20and%20experimental%20pharmacology%20&%20physiology&rft.au=Sheng,%20Fei-Feng&rft.date=2011-08&rft.volume=38&rft.issue=8&rft.spage=550&rft.epage=554&rft.pages=550-554&rft.issn=0305-1870&rft.eissn=1440-1681&rft_id=info:doi/10.1111/j.1440-1681.2011.05548.x&rft_dat=%3Cproquest_pubme%3E879677174%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3578-a5f026bb1360d20dc0b73c84e88f0fb15b0eb01493ef2d89ffb1b61261f0b1993%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=879677174&rft_id=info:pmid/21631570&rfr_iscdi=true |